Comparative Pharmacology
Head-to-head clinical analysis: MAVYRET versus TPOXX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAVYRET versus TPOXX.
MAVYRET vs TPOXX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fixed-dose combination of glecaprevir (NS3/4A protease inhibitor) and pibrentasvir (NS5A inhibitor) that directly inhibits HCV viral replication by targeting viral proteins essential for polyprotein processing and RNA replication.
TPOXX (tecovirimat) inhibits the orthopoxvirus VP37 envelope protein, preventing viral egress from infected cells and reducing viral spread.
Three tablets (containing glecaprevir 100 mg and pibrentasvir 40 mg) taken orally once daily with food for 8 to 16 weeks depending on patient characteristics and prior treatment history.
600 mg orally twice daily for 14 days.
None Documented
None Documented
Glecaprevir: 6 hours; pibrentasvir: 13 hours; supports once-daily dosing.
Terminal half-life ~19 hours (range 10–48 h) in healthy adults; prolonged in renal impairment (up to ~100 h).
Primarily fecal (92%) with unchanged drug (50.3% glecaprevir, 63.8% pibrentasvir); renal elimination is minimal (<1%).
Fecal (primarily as unchanged drug, ~75%); renal (~25%, mostly as metabolites; <2% unchanged in urine).
Category C
Category C
Antiviral Agent
Antiviral Agent